Home » Newsletters » BioWorld Science

BioWorld Science

June 28, 2012

View Archived Issues

New S1P1 receptor agonists prepared by Allergan

Novel PI3K-alpha/mTORC1 inhibitors disclosed by Exelixis

Phase III study planned for MOD-4023

Novo Nordisk presents new long-acting drug for growth hormone deficiency

Lilly diabetes drug substantially decreases HbA1c without delaying recovery from hypoglycemia

Amicus reports preliminary results from phase II study in Pompe's disease

AstraZeneca patents novel agents for arrhythmia

Novel TRPV1 channel antagonists developed at GlaxoSmithKline

Polish team describes new fusion proteins for cancer

Korean researchers present novel protein kinase inhibitors

Merck KGaA designs new hPDK1 inhibitors

New fusion proteins for bone disorders designed in Korea

Research collaboration begins for Parkinson's disease gene therapy

EMA issues scientific opinion on Sanofi Pasteur vaccine

QRxPharma receives complete response letter for MoxDuo

Topica launches phase IIb/III study in onychomycosis

Dosing begins in first-in-human PA-401 trial

New gevokizumab trials initiated in uveitis and erosive osteoarthritis

FDA issues safety communication on cefepime

Depomed acquires rights to liquid-filled capsule analgesic

FDA approves first new weight loss drug in 13 years

Sunesis Pharmaceuticals receives milestone payment for kinase inhibitor program

PTC Therapeutics begins open-label ataluren study

FDA grants premarket approval to noninvasive test to detect prostate cancer

Janssen-Cilag applies for European approval of canagliflozin

CHMP issues opinion on Zyclara MAA

FDA issues complete response letter for Xarelto sNDA

Favorable preclinical profile supports clinical testing of grass pollen vaccine

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...